5-Methoxy-N-propyl-N-isopropyltryptamine (5-MeO-PiPT) is a substituted tryptamine derivative which is claimed to have psychedelic effects. It acts as a 5-HT1A and 5-HT2A receptor agonist,[1] with an EC50 of 13.8 nM and an efficacy of 89% (vs 5-HT),[2] and has been sold as a designer drug, first being identified in 2021 in British Columbia, Canada.[3]

See also

References

  1. ^ Warren AL, Lankri D, Cunningham MJ, Serrano IC, Parise LF, Kruegel AC, Duggan P, Zilberg G, Capper MJ, Havel V, Russo SJ, Sames D, Wacker D (June 2024). "Structural pharmacology and therapeutic potential of 5-methoxytryptamines". Nature. 630 (8015): 237–246. doi:10.1038/s41586-024-07403-2. PMC 11152992. PMID 38720072.
  2. ^ Banister S, Jorgensen W, Jinlong T. Compounds. Patent WO 2023/115167
  3. ^ Knill A, Tobias S, Matthews J, Ti L (June 2022). A Report on British Columbia's Unregulated Drug Supply. Drug checking trends across British Columbia, January to December 2021 (PDF). British Columbia Centre on Substance Use (Report).


No tags for this post.